The nuclear protein fused in sarcoma (FUS) is found in cytoplasmic inclusions in a subset of patients with the neurodegenerative disorder frontotemporal lobar degeneration (FTLD-FUS). FUS contains a methylated arginine-glycine-glycine domain that is required for transport into the nucleus. Recent findings have shown that this domain is hypomethylated in patients with FTLD-FUS. To determine whether the cause of hypomethylation is the result of mutations in protein N-arginine methyltransferases (PRMTs), we selected 3 candidate genes (PRMT1, PRMT3, and PRMT8) and performed complete sequencing analysis and real-time polymerase chain reaction mRNA expression analysis in 20 FTLD-FUS cases. No mutations or statistically significant changes in expression were observed in our patient samples, suggesting that defects in PRMTs are not the cause of FTLD-FUS.

, , , , , ,
doi.org/10.1016/j.neurobiolaging.2013.04.004, hdl.handle.net/1765/40187
Neurobiology of Aging: age-related phenomena, neurodegeneration and neuropathology
Erasmus MC: University Medical Center Rotterdam

Ravenscroft, T., Baker, M., Rutherford, N., Neumann, M., Mackenzie, I., Josephs, K., … Rademakers, R. (2013). Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUS. Neurobiology of Aging: age-related phenomena, neurodegeneration and neuropathology, 34(9). doi:10.1016/j.neurobiolaging.2013.04.004